Seminars in arthritis and rheumatism最新文献

{"title":"Genetics of psoriasis spectrum disease - Advances in targeted therapeutics meeting.","authors":"Anne Barton","doi":"10.1016/j.semarthrit.2025.152665","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152665","url":null,"abstract":"<p><p>▒.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152665"},"PeriodicalIF":4.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice” [Seminars in Arthritis and Rheumatism 71 (2025) 152640]","authors":"Adrián Martín-Gutiérrez ,&nbsp;Javier Loricera ,&nbsp;Vicente Aldasoro ,&nbsp;Olga Maiz ,&nbsp;Eugenio de Miguel ,&nbsp;Eva Galíndez-Agirregoikoa ,&nbsp;Iván Ferraz-Amaro ,&nbsp;Santos Castañeda ,&nbsp;Ricardo Blanco ,&nbsp;Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group","doi":"10.1016/j.semarthrit.2025.152655","DOIUrl":"10.1016/j.semarthrit.2025.152655","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152655"},"PeriodicalIF":4.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combotherapies in immune-mediated inflammatory diseases: A study using the Clinical Data Warehouse from Paris Hospitals’ Public Assistance","authors":"Anne-Laure Gérard ,&nbsp;Matheus Vieira ,&nbsp;Ariel Cohen ,&nbsp;Olivier Hassanaly ,&nbsp;Jérôme Lambert ,&nbsp;David Saadoun","doi":"10.1016/j.semarthrit.2025.152660","DOIUrl":"10.1016/j.semarthrit.2025.152660","url":null,"abstract":"<div><h3>Background</h3><div>The combination of different biological and targeted synthetic DMARDs (<em>i.e.</em>, combotherapy) has recently emerged in the management of immune-mediated inflammatory diseases (IMID). However, real-life data across specialities and prognostic factors related to combotherapy are lacking.</div></div><div><h3>Methods</h3><div>Multicenter observational study conducted using the Clinical Data Warehouse from Paris Hospitals’ Public Assistance including IMID patients under combotherapy, and a matched monotherapy control group. The primary endpoint was the occurrence of serious adverse events (SAE), defined by severe infections, major cardiovascular events, neoplasia and mortality (all-cause).</div></div><div><h3>Results</h3><div>From 42,071 subjects having an IMID, 131 combotherapy lines were identified among 125 patients (median age of 36 years, 58 % females) between 2017 and 2022. The most frequent IMIDs were inflammatory bowel disease (48.8 %), connective tissue diseases (23.2 %), inflammatory myopathies (14.4 %) and vasculitis (11.2 %). After a median follow-up of 15 months [IQR 19], 30 (24 %) patients presented severe infections, 5 (4 %) neoplasia, 4 (3.2 %) venous thromboembolism, 3 (2.4 %) acute coronary syndromes and 7 (5.6 %) deaths. The 1-year cumulative incidence of SAE and severe infections were 29 % (95 %CI 21–38), and 24 % (95 %CI 16–32), respectively. The survival, incidence of SAE and severe infections were not statistically different from combotherapy patients compared to monotherapy controls (n=251) after adjustment for confounders. In multivariate analyses, we found abatacept + JAKi (HR 6.81, 95 %CI 1.88–24.68), anti-IL-1-based (HR 4.82, 95 %CI 1.17–19.89) and anti-CD20-based (HR 4.03, 95 %CI 1.22–13.31) combotherapies to be independently associated with an increased risk of SAE.</div></div><div><h3>Conclusion</h3><div>The overall risk of SAE under combotherapy does not seem greatly increased compared to monotherapy, but certain combinations warrant caution. The combotherapy composition seems predictive of safety outcomes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152660"},"PeriodicalIF":4.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143445524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced imaging in the evaluation of lupus arthritis: A systematic literature review and meta-analysis","authors":"Wei Tang ,&nbsp;Leila Khalili ,&nbsp;Ruoyi Gong ,&nbsp;Maya Souvignier ,&nbsp;Xin Wang ,&nbsp;Shane Murray ,&nbsp;Giovanna Rosas Chavez ,&nbsp;Alberto Nordmann-Gomes ,&nbsp;Laura Geraldino-Pardilla ,&nbsp;Yevgeniya Gartshteyn ,&nbsp;Robert Clancy ,&nbsp;Mandana Nikpour ,&nbsp;Anca Askanase","doi":"10.1016/j.semarthrit.2025.152661","DOIUrl":"10.1016/j.semarthrit.2025.152661","url":null,"abstract":"<div><h3>Introduction</h3><div>Joint involvement is present in up to 95 % of patients with SLE. Arthritis is a main cause of work-related disability and 70–80 % of lupus patients in clinical trials have active joint manifestations.</div></div><div><h3>Objective</h3><div>To review the evidence on the application of musculoskeletal (MSK) ultrasound (US), magnetic resonance imaging (MRI), and optical imaging (OI) in patients with SLE hand and wrist arthritis, discuss measurement properties of US, MRI, and OI, and to provide combined results from these studies.</div></div><div><h3>Methods</h3><div>For this systematic review, three separate population, intervention, comparator, and outcome structured (PICOS) literature searches were conducted for US, MRI and OI using PubMed, EMBASE and the Cochrane Library. The search for US was restricted for the period Jan 1, 2019, to March 31, 2024.</div></div><div><h3>Results</h3><div>Of the 502 identified articles for MSK US, 16 were included. Of the 2101 identified articles for MRI, only 8 were included. Of the 20 identified articles for OI, 1 was included. Data on the use of MSK US, MRI, and OI were evaluated separately regarding reported imaging abnormalities, the definition and scoring of these abnormalities, and measurement properties. Pooled analysis showed strong association between arthritis/arthralgia and US synovitis (10.89 [4.02, 29.48]) and tenosynovitis (5.93 [1.99, 17.72]); association between joint symptoms and US synovitis decreased to 5.00 (1.11, 22.60) when restricted to physician confirmed arthritis.</div></div><div><h3>Conclusion</h3><div>The current systematic literature review examined available information on the use of advanced imaging modalities in the evaluation of hand and wrist involvement in SLE. This literature review demonstrates the need for further research to substantiate the use of advanced imaging as an outcome measure for the MSK manifestations in patients with SLE.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152661"},"PeriodicalIF":4.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of long COVID on self-reported disease activity, disability, and quality of life in individuals with inflammatory arthritis","authors":"Zachary S. Wallace ,&nbsp;Miao Lin ,&nbsp;Shruthi Srivatsan ,&nbsp;Andrew King ,&nbsp;Xiaosong Wang ,&nbsp;Rathnam Venkat ,&nbsp;Yumeko Kawano ,&nbsp;Madison Negron ,&nbsp;Buuthien Hang ,&nbsp;Abigail Schiff ,&nbsp;Jennifer Hanberg ,&nbsp;Emily N. Kowalski ,&nbsp;Colebrook Johnson ,&nbsp;Kathleen M.M. Vanni ,&nbsp;Zachary Williams ,&nbsp;Grace Qian ,&nbsp;Caleb Bolden ,&nbsp;Kevin T. Mueller ,&nbsp;Katarina J. Bade ,&nbsp;Alene A. Saavedra ,&nbsp;Jeffrey A. Sparks","doi":"10.1016/j.semarthrit.2025.152657","DOIUrl":"10.1016/j.semarthrit.2025.152657","url":null,"abstract":"<div><h3>Background</h3><div>People with inflammatory arthritis are at risk for poor COVID-19 outcomes. Little is known about the impact of long COVID on disease activity, disability, and quality of life in this population.</div></div><div><h3>Methods</h3><div>We included participants with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, or axial spondyloarthritis from RheumCARD, a prospective cohort study of people with rheumatic disease with and without prior COVID-19. Long COVID was defined as any symptom of acute COVID-19 for ≥90 days. Surveys include the Routine Assessment of Patient Index Data 3 (RAPID-3), modified health assessment questionnaire (MHAQ), short form-12 (SF-12), fatigue symptom inventory, and short form McGill Pain Questionnaire. We assessed the association of long COVID status with these outcomes.</div></div><div><h3>Results</h3><div>We analyzed n = 59 with long COVID, n = 165 without long COVID, and n = 59 without prior COVID-19. The most common long COVID symptoms were fatigue (37.3 %), altered smell/taste (27.1 % and 25.4 %), difficulty breathing (20.3 %), and headache (15.3 %). Those with vs. without long COVID had worse mHAQ (median 0.4 vs. 0.1, p &lt; 0.001), RAPID-3 (4.0 vs. 2.3, p = 0.0005), and physical and mental health (SF-12: 37.7 vs. 47.2, p = 0.0003 and 45.3 vs. 53.0, p = 0.003, respectively). Fatigue and pain were worse in those with vs. without long COVID (p &lt; 0.05 for comparisons). Similar trends were observed in those with long COVID vs. those without prior COVID-19.</div></div><div><h3>Conclusion</h3><div>Long COVID may result in worsened pain, fatigue, and quality of life in people with inflammatory arthritis. Patient-reported outcomes should be interpreted with caution in people with inflammatory arthritis because of the impact of long COVID.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152657"},"PeriodicalIF":4.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of bone lesions in adults with chronic nonbacterial osteitis (CNO): A long-term follow-up study","authors":"Anne T. Leerling ,&nbsp;Christophe C.J. Weizenbach ,&nbsp;Ana Navas-Cañete ,&nbsp;O.M. Dekkers ,&nbsp;E.M. Winter","doi":"10.1016/j.semarthrit.2025.152658","DOIUrl":"10.1016/j.semarthrit.2025.152658","url":null,"abstract":"<div><h3>Objectives</h3><div>Chronic nonbacterial osteitis (CNO) is a rare disease characterised by sterile bone inflammation. Little is known about the evolution of bone lesions, especially for the adult variant of the disease (adult CNO). We therefore aimed to characterize the radiologic course of adult CNO.</div></div><div><h3>Methods</h3><div>We conducted a cohort study among confirmed adults with CNO, treated at the Dutch national CNO referral centre between 1992 and 2023. Imaging reports from the first-performed radiological scan (baseline) to the last available scan (end of follow-up) were systematically reviewed for lesion location and radiologic features (sclerosis, hyperostosis, erosions, ankylosis). Incidence rates (IRs) for new lesions, progression, and regression of existing lesions were estimated using the Poisson method. Kaplan-Meier curves were used to visualize cumulative incidence, and Poisson regression models assessed associations between patient characteristics and the outcomes.</div></div><div><h3>Results</h3><div>The study included 182 adult CNO patients with a mean follow-up of 6.1 ± 5.2 years, treated with nonsteroidal anti-inflammatory drugs or cyclooxygenase-inhibitors and/or intravenous bisphosphonates or tumour necrosis factor alpha inhibitors. The most common pattern was sole involvement of the anterior chest wall (84 %). IRs per 100 person-years were 4 (95 % CI 3–5) (new lesions), 7 (6–9) (progression), and 1 (0.3.-1) (regression). Among patients with anterior chest wall involvement only (<em>n</em> = 147), one person developed a lesion outside this area (IR 0.3 (0.06–1)). At 2 years, cumulative incidence of new lesion development and progression were 2 % (0–5) and 7 % (3–10), increasing to 11 % (5–17) and 29 % (20–36) at 5 years, and 36 % (23–48) and 56 % (43–64) at 10 years. No associations were found between clinical characteristics at baseline and these outcomes.</div></div><div><h3>Conclusions</h3><div>The development of new bone lesions in treated adult CNO patients is typically confined to previously affected regions, primarily the anterior chest wall. Progression of structural changes occurs in the majority of patients after longer follow-up. These findings can be used for prognostic counselling, and suggest that routine whole-body imaging may not be necessary for most patients during follow-up.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152658"},"PeriodicalIF":4.6,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of exercise-based interventions on inflammatory markers in fibromyalgia: Designing new randomized controlled trials","authors":"André Pontes-Silva","doi":"10.1016/j.semarthrit.2025.152656","DOIUrl":"10.1016/j.semarthrit.2025.152656","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152656"},"PeriodicalIF":4.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Axial bone involvement in sarcoidosis has a good prognosis: Longitudinal study of a cohort of 48 patients","authors":"S Challal ,&nbsp;E Riviere ,&nbsp;B Lanseur ,&nbsp;F Jeny ,&nbsp;H Nunes ,&nbsp;M Soussan ,&nbsp;MC Boissier ,&nbsp;L Semerano ,&nbsp;N Saidenberg-Kermanac'h","doi":"10.1016/j.semarthrit.2025.152654","DOIUrl":"10.1016/j.semarthrit.2025.152654","url":null,"abstract":"<div><h3>Objectives</h3><div>Axial bone involvement in sarcoidosis is observed in approximately 25 % of patients on positron emission tomography (PET). Many of these lesions are asymptomatic, and their long-term outcomes are not well defined. This study aims to evaluate the prognosis of axial bone lesions in histologically confirmed sarcoidosis.</div></div><div><h3>Methods</h3><div>We assessed initial and follow-up MRI and PET from 48 patients diagnosed with axial bone sarcoidosis (135 MRI and 132 PET), with a mean follow-up duration of 33 and 44 months, respectively. Baseline and longitudinal associations between imaging results and patient variables were evaluated.</div></div><div><h3>Results</h3><div>MRI revealed predominantly nodular marrow replacement lesions, while PET identified multifocal bone involvement, with no corresponding bone lesions detected on CT in 80.8 % of cases. Compared to baseline imaging, serial MRI and PET showed significant reduction or resolution of bone lesions over time (MRI: <em>p</em> &lt; 0.01; PET: <em>p</em> &lt; 0.001). This was more frequently observed on PET (68.3 % of patients) than on MRI (19.5). During follow-up, bone pain improved significantly (<em>p</em> = 0.01), which was associated with favorable changes in both PET and MRI findings (<em>p</em> = 0.02 and <em>p</em> = 0.04, respectively). Seven patients had bone relapse. No epiduritis or soft-tissue infiltration was observed.</div></div><div><h3>Discussion</h3><div>This longitudinal evaluation over a 3-year period, combining clinical, radiological, and biochemical data, shows that sarcoidosis axial bone lesions have a favorable prognosis. Significant improvement was observed on both MRI and PET. The improvement in bone pain was associated with favorable imaging changes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152654"},"PeriodicalIF":4.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transformative approaches for effective clinical trials to reduce the disease burden of osteoarthritis","authors":"Constance R. Chu ,&nbsp;Marc Hochberg ,&nbsp;Daniel White ,&nbsp;Scott Rodeo ,&nbsp;Johnny Huard ,&nbsp;Shane Shapiro ,&nbsp;Christian Lattermann ,&nbsp;Farshid Guilak","doi":"10.1016/j.semarthrit.2025.152652","DOIUrl":"10.1016/j.semarthrit.2025.152652","url":null,"abstract":"<div><div>Osteoarthritis (OA) is a leading cause of disability and morbidity that has eluded development of effective disease modifying drugs and therapies. While established OA in the form of symptomatic radiographic disease is a recognizable final common pathway, OA development encompasses a broad spectrum of pathological changes, susceptibilities, and etiological pathways that cannot be considered a single disease process. Beginning with preclinical disease where radiographs are normal, the concept of pre-osteoarthritis (pre-OA) offers a systems-based approach to OA prevention by targeting reduction of OA risk prior to the onset of definable OA. Early OA ensues when cellular, molecular, and joint tissue changes begin to overlap that of OA, a process that can begin before the onset of definitive symptoms or radiographic changes. A myriad of pathways and crossroads of pre-OA and early OA eventually leads to poorly irreversible symptomatic radiographic OA. With increasing recognition of pre-OA and early OA markers, pathways and subtypes, opportunities arise to address these new therapeutic targets. The current status of clinical trials in OA was identified as a critical barrier to progress by the 2022 National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) Roundtable on “Cartilage Preservation and Restoration in Knee Osteoarthritis: Challenges, Gaps, and Opportunities”. This manuscript summarizes the recommendations of the work group established from the Roundtable to address this issue. The work group recommends that clinical trial design and endpoints evolve to effectively evaluate new treatment approaches suitable for pre-osteoarthritis and early OA by different criteria than what has been set for symptomatic radiographic OA. While symptomatic improvement is the primary goal for palliation of irreversible established OA, important goals for treating earlier disease states include disease modification and prevention, with the potential to alter the natural history of progressive OA. Because symptoms may not correlate with structural changes in pre-OA and early OA, the primary outcomes in these trials need to match the intended mechanistic target and the therapeutic goal for the disease state being treated. The purpose of this manuscript is to transform the approach to clinical trials in OA by establishing a new benchmark of identifying critical outcomes that are appropriate for the joint disease states and subtypes of the target patient population, and the therapeutic or mechanistic target of the intervention being tested. By shifting the approach from using standardized outcomes based on established OA towards customizing clinical trials according to these principles, new precision medicine strategies to address the full spectrum of disease from pre-OA to OA can be more readily advanced into clinical practice.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152652"},"PeriodicalIF":4.6,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143438103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between cigarette smoking and radiographic progression in Psoriatic Arthritis","authors":"Fadi Kharouf ,&nbsp;Hernán Maldonado-Ficco ,&nbsp;Shangyi Gao ,&nbsp;Barry J Sheane ,&nbsp;Daniel Pereira ,&nbsp;Vinod Chandran ,&nbsp;Dafna D. Gladman","doi":"10.1016/j.semarthrit.2025.152653","DOIUrl":"10.1016/j.semarthrit.2025.152653","url":null,"abstract":"<div><h3>Objective</h3><div>The association between smoking and radiographic damage has been established in axial spondyloarthritis and rheumatoid arthritis, but not in psoriatic disease. We aimed to investigate this relationship in psoriatic arthritis (PsA).</div></div><div><h3>Methods</h3><div>We included patients with PsA from our observational cohort. Smoking status was assessed at each clinic visit and categorized as non-smoker, past smoker, or current smoker. We used linear mixed models to identify factors associated with the overall change in damage, as measured by the modified Steinbrocker score.</div></div><div><h3>Results</h3><div>Of 1736 patients included in the study, 952 (54.9 %) were males; the mean (standard deviation) age at baseline was 44.9 (13.3) years. 906 (52.2 %) patients were non-smokers, 211 (12.2 %) were past smokers, and 311 (17.9 %) were current smokers; 308 (17.7 %) patients had missing smoking data. The median [interquartile range] modified Steinbrocker score at baseline was 2.0 [0.0, 10.0]. In the multivariable linear mixed model, a longer duration between the first and last sets of radiographs, a higher baseline modified Steinbrocker score, and the use of conventional synthetic DMARDs were significantly associated with an increase in joint damage. Cigarette smoking—both current (estimate -0.18, 95 % confidence interval [CI] -0.94 to 0.58) and past (estimate -0.67, 95 % CI -1.51 to 0.17)—showed no significant association with the change in modified Steinbrcoker score.</div></div><div><h3>Conclusion</h3><div>Cigarette smoking does not appear to be significantly associated with the progression of joint damage in PsA. Further studies are required to confirm our findings.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152653"},"PeriodicalIF":4.6,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143291152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}